An Open Label Multi-Dose-Escalation, Safety and Pharmacokinetic Study of SAR3419 Administered As a Single Agent by Intravenous Infusion Every 3 Weeks in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Coltuximab ravtansine (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors Sanofi
- 13 Feb 2012 Actual patient number 39 added as reported by ClinicalTrials.gov.
- 13 Feb 2012 Actual patient number 39 added as reported by ClinicalTrials.gov.
- 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.